Kymera Ev To Free Cash Flow from 2010 to 2024
| KYMR Stock | USD 40.36 0.30 0.74% |
EV To Free Cash Flow | First Reported 2010-12-31 | Previous Quarter (10.64) | Current Value (10.11) | Quarterly Volatility 47.61325306 |
Check Kymera Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kymera Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 19.5 M, Interest Income of 19.7 M or Depreciation And Amortization of 2.3 M, as well as many indicators such as Price To Sales Ratio of 17.96, Dividend Yield of 0.0 or PTB Ratio of 3.95. Kymera financial statements analysis is a perfect complement when working with Kymera Therapeutics Valuation or Volatility modules.
Kymera | Ev To Free Cash Flow |
Latest Kymera Therapeutics' Ev To Free Cash Flow Growth Pattern
Below is the plot of the Ev To Free Cash Flow of Kymera Therapeutics over the last few years. It is a valuation metric comparing the company's enterprise value to its free cash flow, used to evaluate whether a company is undervalued or overvalued. Kymera Therapeutics' EV To Free Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kymera Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Ev To Free Cash Flow | 10 Years Trend |
|
Ev To Free Cash Flow |
| Timeline |
Kymera Ev To Free Cash Flow Regression Statistics
| Arithmetic Mean | (42.08) | |
| Coefficient Of Variation | (113.15) | |
| Mean Deviation | 39.45 | |
| Median | (74.95) | |
| Standard Deviation | 47.61 | |
| Sample Variance | 2,267 | |
| Range | 157 | |
| R-Value | 0.66 | |
| Mean Square Error | 1,386 | |
| R-Squared | 0.43 | |
| Significance | 0.01 | |
| Slope | 7.00 | |
| Total Sum of Squares | 31,738 |
Kymera Ev To Free Cash Flow History
About Kymera Therapeutics Financial Statements
Kymera Therapeutics shareholders use historical fundamental indicators, such as Ev To Free Cash Flow, to determine how well the company is positioned to perform in the future. Although Kymera Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Kymera Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Kymera Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| EV To Free Cash Flow | (10.64) | (10.11) |
Pair Trading with Kymera Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kymera Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kymera Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Kymera Stock
| 0.53 | CDIOW | Cardio Diagnostics | PairCorr |
| 0.46 | DRTS | Alpha Tau Medical | PairCorr |
| 0.41 | DMAC | DiaMedica Therapeutics Upward Rally | PairCorr |
The ability to find closely correlated positions to Kymera Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kymera Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kymera Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kymera Therapeutics to buy it.
The correlation of Kymera Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kymera Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kymera Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kymera Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Kymera Stock Analysis
When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.